Chronic Inflammatory Demyelinating Polyradiculoneuropathy ( CIDP ) Developing During Tacrolimus Treatment: A Case Series
Muscle & Nerve · 2025
DOI: 10.1002/mus.70025 ↗Kurz gefasst
Fallbericht in der Zeitschrift Muscle & Nerve, 2025. Verfasst von Matthew C Evans und 6 weiteren Autor:innen. Beteiligte Einrichtung: Imperial College Healthcare NHS Trust, London, UK. Hauptthemen laut MEDLINE: Tacrolimus, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Health Research (NIHR), UK Research and Innovation (UKRI) and Versus Arthritis, Pathological Society of Great Britain and Ireland.
Abstract (Originalsprache)
Introduction/Aims Chronic Inflammatory Demyelinating Polyradiculoneuropathy ( CIDP ) can occasionally emerge during treatment with tacrolimus, a commonly used immunosuppressant for solid organ transplantation, and this association is poorly recognized. We describe the clinical presentation, investigations, and disease course of a series of patients who developed CIDP during tacrolimus treatment.
Methods
This is a retrospective case series of six patients with electrophysiologically confirmed CIDP (=2021 EFNS/PNS criteria) during tacrolimus use for solid organ transplantation, evaluated at two UK National Health Service (NHS) trusts between 2017 and 2023. We describe the clinical characteristics, laboratory investigations, neurophysiological features, treatment response, and association with tacrolimus treatment.
Results
CIDP was diagnosed between 5 months and 13 years after initiation of tacrolimus, post cardiac (2), renal (2), lung (1), and combined kidney‐pancreas (1) transplantation. All patients met diagnostic criteria for CIDP. 5/6 patients improved clinically following intravenous immunoglobulin (IVIg). 4/6 patients were switched to either sirolimus or azathioprine without evidence of active disease despite no further treatment. 2/6 patients continued tacrolimus, and both required ongoing IVIg treatment.
Discussion
CIDP may be associated with tacrolimus use in organ transplantation and can occur after years of treatment. IVIg was usually effective in our cohort, and in those who switched to alternative immunosuppression, there was no evidence of active disease after initial treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Imperial College Healthcare NHS Trust, London, UK.
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
ORCID-Profile: Matthew C Evans
Förderung
- National Institute of Health Research (NIHR)
- UK Research and Innovation (UKRI) and Versus Arthritis
- Pathological Society of Great Britain and Ireland
- Wellcome Trust
- GBS|CIDP Foundation International
- University of Oxford's John Fell Fund
- British Medical Association
- UK Research and Innovation
Zitieren
APA
Evans, M. C., Bellanti, R., Dahdaleh, S., Karunaratne, K., Rinaldi, S., Pritchard, J., & Viegas, S. (2025). Chronic Inflammatory Demyelinating Polyradiculoneuropathy ( CIDP ) Developing During Tacrolimus Treatment: A Case Series. Muscle & Nerve. https://doi.org/10.1002/mus.70025
Vancouver
Evans MC, Bellanti R, Dahdaleh S, Karunaratne K, Rinaldi S, Pritchard J, et al. Chronic Inflammatory Demyelinating Polyradiculoneuropathy ( CIDP ) Developing During Tacrolimus Treatment: A Case Series. Muscle & Nerve. 2025. doi:10.1002/mus.70025
BibTeX
@article{Evans2025,
author = {Evans, Matthew C and Bellanti, Roberto and Dahdaleh, Samer and Karunaratne, Kushan and Rinaldi, Simon and Pritchard, Jane and Viegas, Stuart},
title = {Chronic Inflammatory Demyelinating Polyradiculoneuropathy ( CIDP ) Developing During Tacrolimus Treatment: A Case Series},
journal = {Muscle & Nerve},
year = {2025},
doi = {10.1002/mus.70025}
}
EUVIMED